Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance)

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Ryan Sun

Consulting or Advisory Role: Boehringer Ingelheim

Research Funding: Sanofi

Scott Kopetz

Stock and Other Ownership Interests: MolecularMatch, Lutris, Iylon, Frontier Medicines

Consulting or Advisory Role: Genentech, EMD Serono, Merck, Holy Stone Healthcare, Novartis, Lilly, Boehringer Ingelheim, Boston Biomedical, AstraZeneca/MedImmune, Bayer Health, Pierre Fabre, EMD Serono, Redx Pharma, Ipsen, Daiichi Sankyo, Natera, HalioDx, Lutris, Jacobio, Pfizer, Repare Therapeutics, Inivata, GlaxoSmithKline, Jazz Pharmaceuticals, Iylon, Xilis, AbbVie, Amal Therapeutics, Gilead Sciences, Mirati Therapeutics, Flame Biosciences, Servier, Carina Biotech, Bicara Therapeutics, Endeavor BioMedicines, Numab, Johnson & Johnson/Janssen, Genomic Health, Frontier Medicines, Replimune, Taiho Pharmaceutical

Research Funding: Sanofi, Biocartis, Guardant Health, Array BioPharma, Genentech/Roche, EMD Serono, MedImmune, Novartis, Amgen, Lilly, Daiichi Sankyo

Federico Innocenti

Employment: AbbVie

Stock and Other Ownership Interests: AbbVie

Honoraria: Tempus

Consulting or Advisory Role: Symberix, Emerald Lake Safety

Patents, Royalties, Other Intellectual Property: United States Patent: "Flavopiridol drug combinations and methods with reduced side effects", Ratain M.J., Innocenti F., Iyer L. Filed on April 12, 2001, serial number 09/835082, United States Patent: "Optimization of cancer treatment with irinotecan", Ratain M.J., Innocenti F., Karabatsos P., Grimsley C., Di Rienzo A. Filed on February 12, 2003, serial number 60/446942, United States Patent: "Methods of identifying risk of bevacizumab-induced proteinuria and hypertension", Innocenti F., Quintanilha J., Lin D., Owzar K., Wang J. Filed on July 17, 2020, serial number 16/932002, United States Provisional Patent Application: "Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab induced hypertension", Innocenti F., Quintanilha J. Filed on April 1, 2021, serial number 63/169301

Travel, Accommodations, Expenses: AbbVie

Heinz-Josef Lenz

Honoraria: Merck Serono, Roche, Bayer, Boehringer Ingelheim, Isofol Medical, GlaxoSmithKline, G1 THerapeutics, Jazz Pharmaceuticals, Oncocyte, Fulgent Genetics

Consulting or Advisory Role: Merck Serono, Roche, Bayer, BMS, GlaxoSmithKline

Travel, Accommodations, Expenses: Merck Serono, Bayer, BMS

Kanwal Raghav

Consulting or Advisory Role: AstraZeneca, Bayer, Eisai, Daiichi Sankyo

Speakers' Bureau: Bayer

Research Funding: Daiichi Sankyo/Lilly (Inst), Bayer (Inst), Roche/Genentech (Inst), Guardant Health (Inst)

Alan P. Venook

Consulting or Advisory Role: Merck Sharp & Dohme, Amgen, GlaxoSmithKline, Exelixis, BridgeBio Pharma, Bayer Health, Gilead Sciences, Exact Sciences, Bristol Myers Squibb Foundation/Janssen

Research Funding: Amgen

Patents, Royalties, Other Intellectual Property: Royalties from Now-UptoDate for authoring and maintaining two chapters

No other potential conflicts of interest were reported.